NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

about

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

Item

http://www.wikidata.org/entity/Q50569683

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

@en

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

@nl

type

Item

label

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

@en

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

@nl

prefLabel

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

@en

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

@nl

P1476

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

@en

P2093

A H Barnett

http://www.w3.org/2001/XMLSchema#string

D Hicks

http://www.w3.org/2001/XMLSchema#string

D Millar-Jones

http://www.w3.org/2001/XMLSchema#string

J P O'Hare

http://www.w3.org/2001/XMLSchema#string

R D Leslie

http://www.w3.org/2001/XMLSchema#string

S Bain

http://www.w3.org/2001/XMLSchema#string

W Hanif

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence based medicine: what it is and what it isn't

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Personalizing guidelines for diabetes management: twilight or dawn of the expert?

Latent autoimmune diabetes of the adult: current knowledge and uncertainty

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

P304

1398-1403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DME.12952

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281517078

http://www.w3.org/2001/XMLSchema#string

P698

26331592

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes